Fresenius Kabi Oncology Ltd. - Research Center
FKONCO Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 13 | Mar ' 12 | Mar ' 11 | Mar ' 10 | Mar ' 09 | |
|---|---|---|---|---|---|
| Sales | 596.30 | 524.32 | 412.37 | 421.48 | 286.29 |
| Operating profit | 143.00 | 67.45 | 95.98 | 96.64 | -29.29 |
| Interest | -2.60 | 13.07 | 18.03 | 19.40 | 21.97 |
| Gross profit | 147.40 | 55.77 | 84.24 | 83.38 | -51.26 |
| EPS (Rs) | 5.09 | 3.22 | 3.11 | 5.07 | -4.91 |
Annual
results in details
| Mar ' 13 | Mar ' 12 | Mar ' 11 | Mar ' 10 | Mar ' 09 | |
|---|---|---|---|---|---|
| Other income | 1.80 | 1.39 | 6.29 | 6.13 | - |
| Stock adjustment | -31.02 | 6.02 | 7.05 | -30.13 | -26.35 |
| Raw material | 191.74 | 206.05 | 125.28 | 144.77 | 91.73 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 70.32 | 60.98 | 56.11 | 47.59 | 44.51 |
| Excise | - | - | - | - | 11.15 |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | 95.03 | 65.69 | 45.47 | 34.70 | 30.73 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 127.23 | 118.12 | 82.49 | 127.90 | 163.81 |
| Provisions made | - | - | - | - | - |
| Depreciation | 25.79 | 23.97 | 16.92 | 12.51 | 11.81 |
| Taxation | 34.22 | 13.36 | 20.76 | 5.87 | 2.78 |
| Net profit / loss | 80.59 | 50.95 | 49.24 | 80.23 | -77.70 |
| Extra ordinary item | -6.81 | 32.52 | 2.68 | 15.23 | -11.84 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 15.82 | 15.82 | 15.82 | 15.82 | 15.82 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 300.63 | 158.23 | 158.23 | 158.23 | - |
| Agg.of non promotoholding (%) | 19.00 | 10.00 | 10.00 | 10.00 | - |
| OPM (%) | 23.98 | 12.87 | 23.28 | 22.93 | -10.23 |
| GPM (%) | 24.65 | 10.61 | 20.12 | 19.50 | - |
| NPM (%) | 13.47 | 9.69 | 11.76 | 18.76 | - |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis